US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

AgomAb Therapeutics NV (AGMB): Crohn's Disease Biotech Sets Terms Seeking $830m Valuation

AgomAb Therapeutics NV (AGMB): Belgium-Based Biotech Set to IPO with Strong Pharma Backing

AgomAb Therapeutics NV (AGMB): Biotech Selectivity on Display as AgomAb Trades Below IPO Price

IPOs and Secondary Offerings

Equity Capital Markets

AgomAb Therapeutics / Equity Capital Markets

<ul>
<li>AgomAb Therapeutics (AGMB US) filed for a January 16 IPO, targeting a potential February debut to fund mid-stage clinical development in fibrotic diseases.</li>
<li>Lead asset ontunisertib targets fibrostenosing Crohn’s disease via GI-restricted TGFβ/ALK5 inhibition, addressing a large, underserved patient population with no approved therapies.</li>
<li>Backed by ~$330M from blue-chip investors including Fidelity, Redmile, Pfizer, and Sanofi, the company looks to enter public markets with strong validation and balance sheet strength.</li>
</ul>


AgomAb Therapeutics (AGMB US) filed for a January 16 IPO, targeting a potential February debut to fund mid-stage clinical development in fibrotic diseases.
Lead asset ontunisertib targets fibrostenosing Crohn’s disease via GI-restricted TGFβ/ALK5 inhibition, addressing a large, underserved patient population with no approved therapies.
Backed by ~$330M from blue-chip investors including Fidelity, Redmile, Pfizer, and Sanofi, the company looks to enter public markets with strong validation and balance sheet strength.


AgomAb Therapeutics NV (AGMB): Peeking at the IPO Prospectus of a Biotech Targeting Crohn's Disease